Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
1(50.0%)
N/A
1(50.0%)
2Total
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03350269Not ApplicableTerminated

Effect of Lost Wage Reimbursement to Kidney Donors on Living Donation Rates

Role: collaborator

NCT01213329Phase 4Terminated

Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab

Role: collaborator

NCT00096733Completed

Adult-to-Adult Living Donor Liver Transplantation Study

Role: collaborator

All 3 trials loaded